Determining the optimal timing of adjuvant chemotherapy initiation after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

被引:0
|
作者
Cheng, H. [1 ,2 ]
Chen, J. [1 ,2 ]
Jia, G. [1 ,2 ]
Liang, Y. [1 ,2 ]
Li, Y. [1 ,2 ]
Chen, Y. [1 ,2 ]
Lin, J. [1 ,2 ]
Wang, P. [1 ,2 ]
Chen, Q. [1 ,2 ]
Tang, L. [1 ,2 ]
Mai, H. [1 ,2 ]
Liu, L. [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Key Lab Nasopharyngeal Carcinoma Diag & Therapy, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Dept Nasopharyngeal Carcinoma, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China
关键词
locoregionally advanced nasopharyngeal carcinoma; adjuvant chemotherapy initiation; optimal timing; progression-free survival; RANDOMIZED-TRIAL; STAGE-III; CANCER; SURVIVAL; RADIOTHERAPY; ASSOCIATION; MULTICENTER; TIME; DNA;
D O I
10.1016/j.esmoop.2024.103707
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Studies on several malignancies have suggested that the time to commencement of adjuvant chemotherapy (AC) is associated with survival outcomes. There have, however, been no relevant reports of nasopharyngeal carcinoma (NPC). Patients and methods: This clinical study examined newly diagnosed patients between April 2017 and December 2020. The primary endpoint was progression-free survival (PFS). Inverse probability of treatment weighting was used to control for confounding factors. Cox models with restricted cubic splines, Kaplan-Meier method and log-rank tests were used to evaluate the relationship between AC timing and survival. Results: A total of 551 patients were identified [median age, 45 years (interquartile range 36-52 years); 383 (69.5%) male]. Restricted cubic splines demonstrated that the timing of AC initiation had a U-shaped association with PFS. The risk of disease progression decreased within 37 days and subsequently increased. From 37 to 90 days, each additional 7-day delay conferred worse PFS of 1.32 months {hazard ratio (HR): 1.14 [95% confidence interval (CI) 1.01-1.28], P = 0.04}. The cut-off value of the receiver operating characteristic curve for initiation was 69.5 days. At a median follow-up of 48 months, the PFS was significantly better in patients initiated within 69.5 days [HR: 2.18 (95% CI 1.17-4.06), log-rank P = 0.009], with a higher 3-year rate [78.8% (95% CI 75.1% to 82.7%) versus 59.0% (95% CI 42.2% to 82.5%)] than beyond 69.5 days. Positive results were also observed in secondary endpoints. The initiation group was an independent prognostic factor [HR: 2.28 (95% CI 1.42-3.66), P < 0.001]. Conclusions: The optimal timing of AC initiation is similar to 37 days after concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. A delay beyond 69.5 days is associated with compromised survival. Efforts should be made to address the reasons for delays and ensure the timely initiation of AC.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Induction Chemotherapy Plus Concurrent Chemoradiotherapy versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis
    Li, Yang
    Tang, Lin-Quan
    Liu, Li-Ting
    Guo, Shan-Shan
    Liang, Yu-Jing
    Sun, Xue-Song
    Tang, Qing-Nan
    Bei, Jin-Xin
    Tan, Jing
    Chen, Shuai
    Ma, Jun
    Zhao, Chong
    Chen, Qiu-Yan
    Mai, Hai-Qiang
    CANCER RESEARCH AND TREATMENT, 2018, 50 (04): : 1304 - 1315
  • [32] Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone
    Chen, Yu-Pei
    Zhang, Wen-Na
    Tang, Ling-Long
    Mao, Yan-Ping
    Liu, Xu
    Chen, Lei
    Zhou, Guan-Qun
    Mai, Hai-Qiang
    Shao, Jian-Yong
    Jia, Wei-Hua
    Kang, Tie-Bang
    Zeng, Mu-Sheng
    Sun, Ying
    Ma, Jun
    BMC CANCER, 2015, 15
  • [33] Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone
    Yu-Pei Chen
    Wen-Na Zhang
    Ling-Long Tang
    Yan-Ping Mao
    Xu Liu
    Lei Chen
    Guan-Qun Zhou
    Hai-Qiang Mai
    Jian-Yong Shao
    Wei-Hua Jia
    Tie-Bang Kang
    Mu-Sheng Zeng
    Ying Sun
    Jun Ma
    BMC Cancer, 15
  • [34] Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Finding the suitable population
    Wang, Bi-Cheng
    ORAL ONCOLOGY, 2022, 124
  • [35] Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma
    Liu, Li-Ting
    Liang, Yu-Jing
    Guo, Shan-Shan
    Mo, Hao-Yuan
    Guo, Ling
    Wen, Yue-Feng
    Xie, Hao-Jun
    Tang, Qing-Nan
    Sun, Xue-Song
    Liu, Sai-Lan
    Li, Xiao-Yun
    Yang, Jin-Hao
    Yang, Zhen-Chong
    Tang, Lin-Quan
    Chen, Qiu-Yan
    Mai, Hai-Qiang
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [36] TPF induction chemotherapy versus PF adjuvant chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter, randomized controlled, III trial.
    He, Qianyong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] TPF Induction Chemotherapy vs. PF Adjuvant Chemotherapy plus Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Multicenter, Randomized Controlled, III Trial
    Qianyong, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E305 - E305
  • [38] A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma
    Huang, Pei-Yu
    Cao, Ka-Jia
    Guo, Xiang
    Mo, Hao-Yuan
    Guo, Ling
    Xiang, Yan-Qun
    Deng, Man-Quan
    Qiu, Fang
    Cao, Su-Mei
    Guo, Ying
    Zhang, Li
    Li, Ning-Wei
    Sun, Rui
    Chen, Qiu-Yan
    Luo, Dong-Hua
    Hua, Yi-Jun
    Mai, Hai-Qiang
    Hong, Ming-Huang
    ORAL ONCOLOGY, 2012, 48 (10) : 1038 - 1044
  • [39] Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
    Ng, Wai-Tong
    Choi, Cheuk-Wai
    But, Barton
    Ngan, Roger K. C.
    Tung, Stewart
    Cheng, Ashley C.
    Kwong, Dora L. W.
    Lu, Tai-Xiang
    Chan, Anthony T. C.
    Yiu, Harry
    Lee, Sarah
    Wong, Frank
    Yuen, Kam-Tong
    Chappell, Richard J.
    Lee, Anne W. M.
    CLINICAL CANCER RESEARCH, 2022, 28 (12) : 2679 - 2689
  • [40] Concurrent chemoradiotherapy with adjuvant chemotherapy for high-risk nasopharyngeal carcinoma
    Lee, Ching-Chih
    Chu, Sau-Tung
    Chou, Pesus
    AURIS NASUS LARYNX, 2009, 36 (06) : 688 - 694